DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2007 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: GEODON

Summary for Tradename: GEODON

Patents:10
Applicants:2
NDAs:3
Suppliers: see list10
drug
patent expirations by year for
 GEODON

Pharmacology for Tradename: GEODON

Clinical Trials for: GEODON

A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Geodon in Weight Loss Study for Bipolar Disorders
Status: Completed Condition: Bipolar Disorder

Predictors of Response to Augmentation With Ziprasidone (GeodonĀ®) in Major Depressive Disorder
Status: Completed Condition: Depression; Bipolar Disorder

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Status: Completed Condition: Bipolar Disorder; Bipolar Depression; Depression

Geodon (Ziprasidone) for Posttraumatic Stress Disorder
Status: Completed Condition: Posttraumatic Stress Disorder; Post-Traumatic Stress Disorder; PTSD

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Status: Completed Condition: Schizophrenia

Treatment of Schizophrenic Patients With Ziprasidone
Status: Completed Condition: Schizophrenia

Ziprasidone in Pediatric Bipolar Disorder
Status: Completed Condition: Bipolar Disorder

Treatment of Major Depressive Disorder (MDD) With Ziprasidone
Status: Completed Condition: Depression

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
Status: Completed Condition: Schizophrenia; Bipolar Disorder; Schizoaffective Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Pfizer Inc
GEODON
ziprasidone hydrochloride
SUSPENSION; ORAL021483Mar 29, 2006RXYes<disabled><disabled>
Pfizer Inc
GEODON
ziprasidone hydrochloride
SUSPENSION; ORAL021483Mar 29, 2006RXYes4,831,031<disabled><disabled>
Pfizer Inc
GEODON
ziprasidone hydrochloride
SUSPENSION; ORAL021483Mar 29, 2006RXYes5,312,925<disabled><disabled>
Pfizer Inc
GEODON
ziprasidone hydrochloride
SUSPENSION; ORAL021483Mar 29, 2006RXYes6,150,366<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: GEODON

Drugname Dosage Strength RLD Submissiondate
ziprasidone hydrochlorideCapsules20 mg, 40 mg, 60 mg and 80 mgGeodon2/7/2005

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc